吉利德科学 GILD 深 沪
等待开盘 12-23 09:30:00 美东时间
123.97
-0.370
-0.30%
华盛通- 最 高128.16
- 今 开124.00
- 成交量 104.93万股
- 最 低 118.17
- 昨 收 124.34
- 总市值 1554.58亿
- 52周最高 128.70
- 市盈率 静 25.13
- 换手率 0.08%
- 52周最低 88.575
- 委 比 11.74%
- 总股本 12.54亿
- 历史最高 128.70
- 量 比 0.72
- 振 幅 8.03%
- 历史最低 0.195
- 每 手 1
- 风险率 9.22%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多US Medicaid Program Will Hit Swiss Wallets Hard, Roche CEO Says
Roche CEO predicts higher drug costs in Switzerland due to U.S. government's deals with pharmaceutical companies.
12-22 21:43
Why Health Care ETFs Aren't Panicking Over Big Pharma's Price Cuts
Healthcare ETFs stay resilient as Big Pharma agrees to Medicaid drug price cuts. Here's what is cushioning ETFs despite pricing pressure.
12-20 04:17
MHRA Approves Lenacapavir For The Prevention Of Sexually Transmitted HIV-1 Infection
https://www.gov.uk/government/news/mhra-approves-lenacapavir-for-the-prevention-of-sexually-transmitted-hiv-1-infection
12-19 23:14
White House Readies Drug Price Deals With AbbVie, Novartis, Roche
AbbVie and other drugmakers may announce U.S. drug pricing deals on Friday as the White House pushes lower prices and Medicare payment reforms.
12-18 23:14
Gilead's Experimental Combo Tablet For HIV Treatment Hits Primary Goal
Gilead said its two-drug bictegravir-lenacapavir tablet was non-inferior to Biktarvy in the Phase 3 ARTISTRY-2 HIV trial.
12-16 01:15
Arcus Revamps Cancer Pipeline Following Trial Miss, Prioritizes Kidney Drug
Arcus ends its Phase 3 STAR-221 trial after a futility review and shifts R&D toward casdatifan, supported by strong early RCC data and key 2026 milestones.
12-13 02:35
Arcus Biosciences Discontinues Phase 3 STAR-221 Study With Gilead Following IDMC Futility Recommendation
The Phase 3 STAR-221 study evaluating a domvanalimab-based combination in upper gastrointestinal cancers will be discontinued due to futilityArcus is continuing to expand its development program for casdatifan, a
12-12 21:33
Why Is Arcellx Stock Surging Today?
Arcellx shares updated ASH data showing strong response and survival results for anito-cel in relapsed multiple myeloma, with analysts highlighting its emerging profile.
12-09 02:23
What Does the Market Think About Gilead Sciences Inc?
Gilead Sciences Inc's (NYSE:GILD) short interest as a percent of float has fall...
12-08 21:00
重磅！云顶新耀前高管加入GSK中国
（来源：CHC医疗传媒） 据21世纪经济报道，盛锋于2025年12月1日加入GSK中国，担任副总裁、市场准入与商业运营(MACO)负责人。他将直接向副总裁、G...
12-02 15:01
